国际生殖健康/计划生育杂志

国际生殖健康/计划生育 ›› 2019, Vol. 38 ›› Issue (3): 209-213.

• 论著 • 上一篇    下一篇

子宫内膜癌组织中叶酸受体α与CA125的表达及临床意义

周洋，孙昊，金志军，吴玉仙，王成才   

  1. 200003上海，第二军医大学附属长征医院
  • 收稿日期:2019-01-31 修回日期:2019-03-28 出版日期:2019-05-15 发布日期:2019-05-16
  • 通讯作者: 王成才，E-mail:wangchengcai81@sina.com；吴玉仙，E-mail: wuyuxian76@163.com E-mail:wangchengcai81@sina.com

Expressions of Folate Receptor Alpha and CA125 in Endometrial Carcinoma Tissues

ZHOU Yang, SUN Hao, JIN Zhi-jun, WU Yu-xian, WANG Cheng-cai   

  1. Changzheng Hospital of the Second Military Medical University, Shanghai 200003, China
  • Received:2019-01-31 Revised:2019-03-28 Published:2019-05-15 Online:2019-05-16
  • Contact: WANG Cheng-ｃａｉ，E-mail:wangchengcai81@sina.ｃｏｍ；ＷＵ Ｙｕ－ｘｉａｎ，Ｅ－ｍａｉｌ： ｗｕｙｕｘｉａｎ７６＠ １６３．ｃｏｍ E-mail:wangchengcai81@sina.com

PDF (PC)

8908

摘要： 目的：检测子宫内膜癌（EC）组织中叶酸受体α（FRα）和糖类抗原125（CA125）的表达，分析其在EC发生、进展和预后中的作用。方法：选取2015年7月—2018年12月我院收治的62例EC患者作为EC组，选取同期42例子宫内膜非典型增生患者为非典型增生组，42例正常子宫内膜患者为正常对照组。采用免疫组织化学方法测定对比3组子宫内膜组织中FRα、CA125的高表达率情况，并比较EC组患者不同肿瘤大小、分化程度、临床分期、淋巴结转移、肌层浸润深度者FRα、CA125的表达差异，观察EC组子宫内膜组织中FRα与CA125表达的相关性。同时对EC组中术后满1年患者共53例进行随访，分析组织FRα、CA125表达与EC患者术后1年复发率的关系。结果：EC组中FRα、CA125的高表达率均高于非典型增生组及正常对照组（P＜0.05）；EC组患者不同肿瘤大小、有无淋巴结转移者之间FRα、CA125的表达差异无统计学意义（P＞0.05）；肿瘤分化程度为G2～G3、临床分期为Ⅲ～Ⅳ期、肌层浸润深度≥1/2的EC组患者FRα、CA125高表达率均高于肿瘤分化程度为G1、临床分期为Ⅰ～Ⅱ期、肌层浸润深度＜1/2者（均P＜0.05）；经Spearman相关性分析证实，EC组患者子宫内膜组织中FRα与CA125表达呈正相关（rs=0.328，P=0.009）；EC组子宫内膜组织中FRα与CA125呈高表达者术后1年复发率与低表达者比较，差异无统计学意义（P＞0.05）。结论：EC组织中FRα、CA125均呈高表达且有相关性。可尝试检测FRα和CA125表达，作为EC病理诊断、恶性程度评价的指标。

关键词: 子宫内膜肿瘤, 癌, 叶酸受体α, 叶酸, CA-125抗原, 细胞分化, 肿瘤分期

Abstract: Objective：To investigate the expressions of folate receptor alpha (FRα) and carbohydrate antigen 125 (CA125) in the endometrial cancer (EC) tissues, and to analyze their possible roles in the occurrence，progression and prognosis of EC. Methods: The 62 patients with EC who were admitted to our hospital from July 2015 to December 2018 were selected as the EC group. 42 patients with atypical hyperplasia of the endometrium were selected as the atypical hyperplasia group and 42 patients with normal endometrium as the normal group. The expressions of FRα and CA125 in the endometrial tissues were tested by immunohistochemistry. The tumor size, differentiation degree, clinical stage, lymph node metastasis and the myometrial invasion depth were compared in those patients with EC. The relationship between FRα and CA125 expression, and the one-year recurrence rate of EC patients, was analyzed. Results: The positive rates of FRα and CA125 expression in the endometrial tissues of the EC group were higher than those in the atypical hyperplasia group and the normal control group (all P＜0.05). There were no significant differences in the expressions of FRα and CA125 between EC patients with different tumor size and lymph node metastasis (P＞0.05). The expressions of FRα and CA125 in the EC patients with the degree of tumor differentiation from G2 to G3, clinical stage Ⅲ to Ⅳ, and the myometrial invasion depth ≥ 1/2 were higher than those in those EC patients with tumor differentiation G1, clinical stage Ⅰto Ⅱ, and the myometrial invasion depth ＜1/2 (P＜0.05). The Spearman correlation analysis confirmed that there was a positive correlation between FRα and CA125 expression in the endometrial tissues of the EC group（rs=0.328，P=0.009）. The one-year recurrence rate in the patients with higher expressions of FRα and CA125 was higher than that in other patients with lower expressions, but the difference was not significant (P＞0.05). Conclusions: The expressions of both FRα and CA125 in the EC tissues are increased. Both FRα and CA125 can be used as the possible indicators for the pathological diagnosis and malignant degree evaluation of EC.

Key words: Endometrial neoplasms, Carcinoma, Folate receptor alpha, Folic acid, CA-125 antigen, Cell differentiation, Neoplasm staging